Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | — | 2 | — | — | — | 2 |
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
Hepatitis | D006505 | HP_0012115 | K75.9 | — | 1 | — | — | — | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | — | 1 |
Drug common name | NIVOCASAN |
INN | nivocasan |
Description | Nivocasan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | caspase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1 |
PDB | — |
CAS-ID | 908253-63-4 |
RxCUI | — |
ChEMBL ID | CHEMBL2105721 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 9554OW6MVU (ChemIDplus, GSRS) |